Literature DB >> 17239952

Risk of resistance associated with fluconazole prophylaxis: systematic review.

Luc P Brion1, Smart E Uko, David L Goldman.   

Abstract

BACKGROUND: Several studies have shown that fluconazole prophylaxis reduces the risk of fungal colonization and of invasive fungal infection in high-risk patients with minimal toxicity. This systematic review was designed to estimate the risk of emergence of colonization and infection either with azole susceptible-dose dependent or with resistant strains.
METHODS: We searched Medline, EMBASE, the Cochrane Collaboration database and our own files for randomized controlled trials assessing the effect of fluconazole on the incidence of fluconazole-resistant strains.
RESULTS: This systematic review of randomized clinical trials shows that fluconazole prophylaxis increases the risk for colonization with fluconazole susceptible-dose dependent or with resistant yeasts, the percentage of non-albicans Candida isolates and the percentage of fluconazole susceptible-dose dependent or resistant fungal isolates. Fluconazole prophylaxis did not significantly affect the risk of invasive disease with fluconazole susceptible-dose dependent or resistant fungi. The sample size was too small to assess the effect of fluconazole prophylaxis on the risk for breakthrough infections with non-albicans Candida.
CONCLUSION: Evidence from randomized trials suggests that fluconazole prophylaxis increases the risk for colonization with fluconazole susceptible-dose dependent or with resistant fungi, but does not significantly affect the risk for invasive infections with fluconazole susceptible-dose dependent or with resistant fungi. The risk for breakthrough infections remains a concern and needs to be addressed in large prospective studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239952     DOI: 10.1016/j.jinf.2006.11.017

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

Review 1.  Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.

Authors:  Jemma Cleminson; Nicola Austin; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2015-10-24

Review 2.  Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.

Authors:  Nicola Austin; Jemma Cleminson; Brian A Darlow; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2015-10-24

3.  On track to limit antifungal overuse!

Authors:  Philippe Eggimann; Frédéric Lamoth; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-02-11       Impact factor: 17.440

Review 4.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

5.  Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment.

Authors:  John W Baddley; Senu Apewokin
Journal:  Curr Fungal Infect Rep       Date:  2008-05-30

6.  Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata.

Authors:  Patrick Vandeputte; Laurent Pineau; Gérald Larcher; Thierry Noel; Daniel Brèthes; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Mycopathologia       Date:  2010-07-09       Impact factor: 2.574

7.  Diagnosis and Management of Cryptococcal Relapse.

Authors:  Abdu K Musubire; David R Boulware; David B Meya; Joshua Rhein
Journal:  J AIDS Clin Res       Date:  2013-04-29

8.  High-Resolution SNP/CGH Microarrays Reveal the Accumulation of Loss of Heterozygosity in Commonly Used Candida albicans Strains.

Authors:  Darren Abbey; Meleah Hickman; David Gresham; Judith Berman
Journal:  G3 (Bethesda)       Date:  2011-12-01       Impact factor: 3.154

9.  Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans.

Authors:  Popchai Ngamskulrungroj; Yun Chang; Bryan Hansen; Cliff Bugge; Elizabeth Fischer; Kyung J Kwon-Chung
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

10.  Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis.

Authors:  Diego C Rossi; Julian E Muñoz; Danielle D Carvalho; Rodrigo Belmonte; Bluma Faintuch; Primavera Borelli; Antonio Miranda; Carlos P Taborda; Sirlei Daffre
Journal:  BMC Microbiol       Date:  2012-03-06       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.